This page/content is for Great Britain healthcare professionals only.

Pluvicto® is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.²

 

mCRPC and PSMA

When patients progress to mCRPC their prognosis decreases significantly^3,4